An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed.

Finerenone has been shown to significantly reduce the risk for cardiovascular death in patients with heart failure in results from the FINEARTS-HF trial.

The Lancet published a new pooled, participant-level analysis of patients with heart failure with mildly reduced ejection ...

led to an 18% reduction in cardiovascular death or worsening heart failure in patients with both mildly reduced and preserved ejection fraction, said AZ. Ejection fraction is a measure of how much ...

The medication, finerenone, could be an effective therapy in people with heart failure who have mildly reduced or preserved ejection fraction, suggests the study, published Sunday in the New Engla ...

The weight-loss jab Wegovy has been hailed as an “absolute game-changer” after a new study showed that it relieved symptoms ...

This meta-analysis investigated the effects of mineralocorticoid receptor antagonists (MRAs) using data from nearly 14,000 patients with heart failure (HF) from four trials.  MRAs reduced the risk of ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.